Solstein Capital LLC Increases Stake in Lam Research Corporation $LRCX

Solstein Capital LLC lifted its stake in shares of Lam Research Corporation (NASDAQ:LRCX) by 742.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 590 shares of the semiconductor company’s stock after acquiring an additional 520 shares during the period. Solstein Capital LLC’s holdings in Lam Research were worth $57,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Envestnet Asset Management Inc. raised its holdings in Lam Research by 12.1% in the second quarter. Envestnet Asset Management Inc. now owns 3,495,415 shares of the semiconductor company’s stock valued at $340,244,000 after buying an additional 378,090 shares during the period. Nisa Investment Advisors LLC raised its holdings in Lam Research by 28.9% in the second quarter. Nisa Investment Advisors LLC now owns 537,348 shares of the semiconductor company’s stock valued at $52,428,000 after buying an additional 120,328 shares during the period. Oppenheimer Asset Management Inc. raised its holdings in Lam Research by 528.7% in the second quarter. Oppenheimer Asset Management Inc. now owns 23,123 shares of the semiconductor company’s stock valued at $2,251,000 after buying an additional 19,445 shares during the period. Prudent Man Advisors LLC raised its holdings in Lam Research by 20.3% in the second quarter. Prudent Man Advisors LLC now owns 17,752 shares of the semiconductor company’s stock valued at $1,728,000 after buying an additional 2,993 shares during the period. Finally, Optimum Investment Advisors raised its holdings in Lam Research by 4.9% in the second quarter. Optimum Investment Advisors now owns 9,700 shares of the semiconductor company’s stock valued at $944,000 after buying an additional 450 shares during the period. Hedge funds and other institutional investors own 84.61% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on LRCX. Summit Insights lowered shares of Lam Research from a “buy” rating to a “hold” rating in a report on Thursday, July 31st. Berenberg Bank raised their price target on shares of Lam Research from $122.00 to $165.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Wall Street Zen raised shares of Lam Research from a “hold” rating to a “buy” rating in a research report on Saturday, October 4th. JPMorgan Chase & Co. increased their price objective on shares of Lam Research from $113.00 to $165.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Finally, Mizuho increased their price objective on shares of Lam Research from $162.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-six have assigned a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $148.83.

Lam Research Stock Up 3.4%

LRCX stock opened at $156.90 on Tuesday. Lam Research Corporation has a twelve month low of $56.32 and a twelve month high of $158.25. The company has a current ratio of 2.21, a quick ratio of 1.60 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $197.86 billion, a P/E ratio of 34.56, a PEG ratio of 1.66 and a beta of 1.84. The firm has a 50 day simple moving average of $124.39 and a 200-day simple moving average of $100.67.

Lam Research (NASDAQ:LRCX) last released its quarterly earnings results on Wednesday, October 22nd. The semiconductor company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.04. Lam Research had a net margin of 29.66% and a return on equity of 60.60%. The business had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.23 billion. During the same quarter last year, the company earned $0.86 earnings per share. The business’s quarterly revenue was up 27.7% compared to the same quarter last year. Lam Research has set its Q2 2026 guidance at 1.050-1.250 EPS. On average, equities research analysts predict that Lam Research Corporation will post 3.71 earnings per share for the current fiscal year.

Lam Research Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 15th. Stockholders of record on Wednesday, September 24th were given a dividend of $0.26 per share. The ex-dividend date of this dividend was Wednesday, September 24th. This is an increase from Lam Research’s previous quarterly dividend of $0.23. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.7%. Lam Research’s dividend payout ratio is 22.91%.

Insider Buying and Selling at Lam Research

In other news, SVP Vahid Vahedi sold 52,190 shares of the firm’s stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $138.90, for a total transaction of $7,249,191.00. Following the completion of the sale, the senior vice president owned 251,047 shares of the company’s stock, valued at approximately $34,870,428.30. This trade represents a 17.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.31% of the company’s stock.

Lam Research Company Profile

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.